Does the media refer more to AXSM or JAZZ?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 11 mentions for Axsome Therapeutics and 8 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.01 beat Jazz Pharmaceuticals' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate JAZZ or TAK?

Jazz Pharmaceuticals currently has a consensus price target of $285.44, suggesting a potential upside of 19.33%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media favor JAZZ or TAK?

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Jazz Pharmaceuticals and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or ONC?

In the previous week, BeOne Medicines had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 10 mentions for BeOne Medicines and 8 mentions for Jazz Pharmaceuticals. BeOne Medicines' average media sentiment score of 0.97 beat Jazz Pharmaceuticals' score of 0.39 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or RPRX?

In the previous week, Royalty Pharma had 1 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for Royalty Pharma and 8 mentions for Jazz Pharmaceuticals. Royalty Pharma's average media sentiment score of 0.52 beat Jazz Pharmaceuticals' score of 0.39 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$239.20 -0.87 (-0.36%)

As of 02:51 PM Eastern

Compare

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

Should you buy Jazz Pharmaceuticals stock or one of its competitors? Jazz Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Royalty Pharma (RPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.28	-$183.17M	-$3.75	N/A
Jazz Pharmaceuticals	$4.60B	3.37	-$356.15M	$14.50	16.50

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

In the previous week, Axsome Therapeutics had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 11 mentions for Axsome Therapeutics and 8 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.01 beat Jazz Pharmaceuticals' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics presently has a consensus price target of $267.60, indicating a potential upside of 27.02%. Jazz Pharmaceuticals has a consensus price target of $285.44, indicating a potential upside of 19.33%. Given Axsome Therapeutics' higher probable upside, research analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Jazz Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Jazz Pharmaceuticals has higher earnings, but lower revenue than Takeda Pharmaceutical. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.37	-$356.15M	$14.50	16.50
Takeda Pharmaceutical	$28.32B	2.06	-$1.01B	$0.34	53.63

Jazz Pharmaceuticals has a net margin of 20.45% compared to Takeda Pharmaceutical's net margin of 3.80%. Jazz Pharmaceuticals' return on equity of 33.97% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Jazz Pharmaceuticals currently has a consensus price target of $285.44, suggesting a potential upside of 19.33%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Jazz Pharmaceuticals and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Takeda Pharmaceutical on 13 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Jazz Pharmaceuticals' return on equity of 33.97% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Jazz Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Jazz Pharmaceuticals currently has a consensus price target of $285.44, suggesting a potential upside of 19.33%. Teva Pharmaceutical Industries has a consensus price target of $43.10, suggesting a potential upside of 18.01%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Jazz Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Teva Pharmaceutical Industries has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.37	-$356.15M	$14.50	16.50
Teva Pharmaceutical Industries	$17.26B	2.47	$1.41B	$0.60	60.87

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 8 mentions for Jazz Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 0.87 beat Jazz Pharmaceuticals' score of 0.39 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	7 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

BeOne Medicines has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.37	-$356.15M	$14.50	16.50
BeOne Medicines	$6.13B	6.26	$286.93M	$5.68	61.56

Jazz Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

In the previous week, BeOne Medicines had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 10 mentions for BeOne Medicines and 8 mentions for Jazz Pharmaceuticals. BeOne Medicines' average media sentiment score of 0.97 beat Jazz Pharmaceuticals' score of 0.39 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals presently has a consensus price target of $285.44, indicating a potential upside of 19.33%. BeOne Medicines has a consensus price target of $402.14, indicating a potential upside of 15.01%. Given Jazz Pharmaceuticals' higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 20.45% compared to BeOne Medicines' net margin of 10.70%. Jazz Pharmaceuticals' return on equity of 33.97% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
BeOne Medicines	10.70%	14.23%	7.82%

Summary

BeOne Medicines beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Royalty Pharma has a net margin of 32.14% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Royalty Pharma	32.14%	30.01%	14.91%

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.37	-$356.15M	$14.50	16.50
Royalty Pharma	$2.38B	14.57	$770.95M	$1.45	41.56

Jazz Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

In the previous week, Royalty Pharma had 1 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for Royalty Pharma and 8 mentions for Jazz Pharmaceuticals. Royalty Pharma's average media sentiment score of 0.52 beat Jazz Pharmaceuticals' score of 0.39 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals currently has a consensus target price of $285.44, suggesting a potential upside of 19.33%. Royalty Pharma has a consensus target price of $61.29, suggesting a potential upside of 1.70%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.53B	$12.41B	$7.15B	$12.79B
Dividend Yield	N/A	2.59%	2.54%	9.15%
P/E Ratio	16.50	789.78	271.90	25.27
Price / Sales	3.37	756.72	697.54	108.08
Price / Cash	15.18	90.26	77.07	52.39
Price / Book	3.37	10.62	10.81	6.34
Net Income	-$356.15M	$2.82B	$3.48B	$357.86M
7 Day Performance	-2.59%	-1.78%	-0.91%	-0.06%
1 Month Performance	-6.77%	2.99%	2.70%	-0.94%
1 Year Performance	86.10%	5.22%	21.40%	11.89%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	4.3564 of 5 stars	$239.20 -0.4%	$285.44 +19.3%	+84.9%	$15.53B	$4.60B	16.50	2,890
AXSM Axsome Therapeutics	4.3257 of 5 stars	$198.52 -0.3%	$267.60 +34.8%	+60.7%	$10.42B	$638.50M	N/A	380
TAK Takeda Pharmaceutical	1.7122 of 5 stars	$18.00 -0.2%	N/A	+19.9%	$57.77B	$28.32B	52.94	47,000
TEVA Teva Pharmaceutical Industries	4.2116 of 5 stars	$36.03 -1.1%	$42.22 +17.2%	+90.7%	$42.46B	$17.26B	60.05	33,950	Analyst Forecast
ONC BeOne Medicines	4.3116 of 5 stars	$359.58 -1.9%	$402.14 +11.8%	+1.5%	$40.26B	$5.34B	63.31	12,000	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Which has better valuation & earnings, AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Does the media refer more to AXSM or JAZZ?

Do analysts rate AXSM or JAZZ?

Which has more risk and volatility, AXSM or JAZZ?

Do insiders and institutionals believe in AXSM or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Which has more risk and volatility, JAZZ or TAK?

Which has higher earnings and valuation, JAZZ or TAK?

Is JAZZ or TAK more profitable?

Do analysts rate JAZZ or TAK?

Does the media favor JAZZ or TAK?

Do institutionals and insiders hold more shares of JAZZ or TAK?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Is JAZZ or TEVA more profitable?

Which has more risk and volatility, JAZZ or TEVA?

Do analysts prefer JAZZ or TEVA?

Which has preferable earnings and valuation, JAZZ or TEVA?

Does the media favor JAZZ or TEVA?

Do institutionals and insiders hold more shares of JAZZ or TEVA?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Which has preferable earnings & valuation, JAZZ or ONC?

Which has more risk & volatility, JAZZ or ONC?

Does the media refer more to JAZZ or ONC?

Do analysts rate JAZZ or ONC?

Do institutionals & insiders believe in JAZZ or ONC?

Is JAZZ or ONC more profitable?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Is JAZZ or RPRX more profitable?

Which has stronger valuation & earnings, JAZZ or RPRX?

Which has more volatility & risk, JAZZ or RPRX?

Does the media refer more to JAZZ or RPRX?

Do analysts recommend JAZZ or RPRX?

Do insiders and institutionals have more ownership in JAZZ or RPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools